Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-03-29-Speech-4-108"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070329.23.4-108"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
I voted in favour of this revision.
Although it is regrettable that the proposal for the prohibition of medical products containing substances that are carcinogenic, mutagenic or toxic to reproduction has been defeated, this compromise does nevertheless constitute a decisive first step, one that will help to eliminate the use in medical products of toxic chemical substances that are then found in the bodies of patients. The legislation will require that makers of medical equipment label them when they contain phthalates, which belong to a family of chemical substances used to soften plastic.
The European Union has classified the phthalate DEHP as a substance toxic to human reproduction, and there is serious concern about the possibility of it finding its way from the apparatus into patients, babies and dialysis patients in particular.
The labelling of products will alert doctors to the risk of their patients being exposed to them, and those responsible for buying equipment for hospitals will easily be able to identify those plastic goods without DEHP that are already available on the market. Manufacturers will be required to provide explanation of the risks vulnerable patients involved in the use of the equipment containing toxic chemical substances and to suggest precautionary measures."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples